Download
s40266-020-00771-0.pdf 656,48KB
WeightNameValue
1000 Titel
  • A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019)
1000 Autor/in
  1. Pazan, Farhad |
  2. Collins, Ronan |
  3. Gil, Victor M. |
  4. Hanon, Olivier |
  5. Hardt, Roland |
  6. Hoffmeister, Martin |
  7. Monteiro, Pedro |
  8. Quinn, Terence J. |
  9. Ropers, Dieter |
  10. Sergi, Giuseppe |
  11. Verheugt, Freek W. A. |
  12. Wehling, Martin |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-05
1000 Erschienen in
1000 Quellenangabe
  • 37(7):539-548
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40266-020-00771-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203545/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Introduction!#!Evidence regarding safety and efficacy of oral anticoagulants for the treatment of atrial fibrillation (AFib) in older adults has been assessed regarding the age appropriateness of oral anticoagulants (OAC) according to the FORTA (Fit fOR The Aged) classification (OAC-FORTA). Three years after its first version (OAC-FORTA 2016), an update was initiated to create OAC-FORTA 2019.!##!Methods!#!A structured review of randomized controlled clinical trials and summaries of individual product characteristics was performed to detect newly emerged evidence on oral anticoagulants in older patients with AFib. This review was used by an interdisciplinary panel of European experts (N = 10) in a Delphi process to label OACs according to FORTA.!##!Results!#!A total of 202 records were identified and 11 studies finally included. We found four new trials providing relevant data on efficacy and safety of warfarin, apixaban, dabigatran or rivaroxaban in older patients with AFib. In the majority of studies comparing the non-vitamin-K oral anticoagulants (NOACs) with warfarin, NOACs were superior to warfarin regarding at least one relevant clinical endpoint. The mean consensus coefficient significantly increased from 0.867 (OAC-FORTA 2016) to 0.931 (p < 0.05) and the proposed FORTA classes were confirmed in all cases during the first round (consensus coefficient > 0.8). Warfarin, dabigatran, edoxaban and rivaroxaban were assigned to the FORTA B label, acenocoumarol, fluindione and phenprocoumon were labeled FORTA C and only apixaban was rated as FORTA A.!##!Conclusion!#!OAC-FORTA 2019 confirms that AFib can be successfully treated with positively labeled antithrombotics at advanced age.
1000 Sacherschließung
lokal Warfarin/therapeutic use [MeSH]
lokal Anticoagulants/administration
lokal Warfarin/administration
lokal Aged [MeSH]
lokal Pyrazoles/therapeutic use [MeSH]
lokal Atrial Fibrillation/drug therapy [MeSH]
lokal Pyridones/administration
lokal Administration, Oral [MeSH]
lokal Dabigatran/administration
lokal Pyridones/therapeutic use [MeSH]
lokal Consensus Development Conferences as Topic [MeSH]
lokal Randomized Controlled Trials as Topic [MeSH]
lokal Vitamin K/antagonists
lokal Male [MeSH]
lokal Original Research Article
lokal Long-Term Care/methods [MeSH]
lokal Internal Medicine
lokal Pharmacotherapy
lokal Europe [MeSH]
lokal Female [MeSH]
lokal Pharmacology/Toxicology
lokal Dabigatran/therapeutic use [MeSH]
lokal Geriatrics/Gerontology
lokal Humans [MeSH]
lokal Rivaroxaban/therapeutic use [MeSH]
lokal Pyrazoles/administration
lokal Anticoagulants/therapeutic use [MeSH]
lokal Rivaroxaban/administration
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UGF6YW4sIEZhcmhhZA==|https://frl.publisso.de/adhoc/uri/Q29sbGlucywgUm9uYW4=|https://frl.publisso.de/adhoc/uri/R2lsLCBWaWN0b3IgTS4=|https://frl.publisso.de/adhoc/uri/SGFub24sIE9saXZpZXI=|https://frl.publisso.de/adhoc/uri/SGFyZHQsIFJvbGFuZA==|https://frl.publisso.de/adhoc/uri/SG9mZm1laXN0ZXIsIE1hcnRpbg==|https://frl.publisso.de/adhoc/uri/TW9udGVpcm8sIFBlZHJv|https://frl.publisso.de/adhoc/uri/UXVpbm4sIFRlcmVuY2UgSi4=|https://frl.publisso.de/adhoc/uri/Um9wZXJzLCBEaWV0ZXI=|https://frl.publisso.de/adhoc/uri/U2VyZ2ksIEdpdXNlcHBl|https://frl.publisso.de/adhoc/uri/VmVyaGV1Z3QsIEZyZWVrIFcuIEEu|https://frl.publisso.de/adhoc/uri/V2VobGluZywgTWFydGlu
1000 Hinweis
  • DeepGreen-ID: bdc6314f1f15455a96986e6cf2220359 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6465109.rdf
1000 Erstellt am 2023-11-16T10:07:50.402+0100
1000 Erstellt von 322
1000 beschreibt frl:6465109
1000 Zuletzt bearbeitet 2023-12-01T01:37:43.220+0100
1000 Objekt bearb. Fri Dec 01 01:37:43 CET 2023
1000 Vgl. frl:6465109
1000 Oai Id
  1. oai:frl.publisso.de:frl:6465109 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source